Synedgen’s Glycopolymer Technology Licensed to Synspira Therapeutics Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease

Synspira Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis and other rare diseases, today announced the results of a publication exploring the efficacy of SNSP113 as a potential treatment for improving lung function in people with cystic fibrosis. The publication, “A glycopolymer improves viscoelasticity and mucociliary transport of abnormal cystic fibrosis mucus” was published in the April issue of The Journal of Clinical Investigation and evaluated a number of mechanisms where SNSP113 could impact abnormal mucus structure and improve mucus clearance.